Topical gel for migraine shows promise in trials, can penetrate transdermal barrier

A novel topical gel for treating migraines showed promise in a clinical trial: 77% of patients experienced pain relief. Advantages of the new transdermal approach include delivery directly to the affected nerves and tissue. By bypassing the digestive system, the drug avoids systematic circulation in the body. This limits side effects and enables fast action. North Carolina's Achelios Therapeutics says its formulation facilitates superior penetrations of the active ingredient (an over-the-counter, anti-inflammatory molecule called ketoprofen) through the skin, for overcoming the dermal barrier has been a challenge for other topical treatments. Dubbed Topofen, the candidate is ready for Phase IIb trials. More about the trial (reg. req.) | Here's more info about Achelios

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…